

> 定義 (Diabetes Care 2019;42:S13)


# DIABETES MELLITUS

定義 (_Diabetes Care_ 2019;42:S13)

• Either HbA1c ≥6.5, fasting glc ≥126 mg/dL, or glc 2 h after OGTT ≥200 mg/dL × 2 (for any test) or single random glc ≥200 mg/dL with classic sx of hyperglycemia; all tests equally reasonable (nb, may be ⊕ on one test but not another); OGTT preferred during preg

• Blood glc higher than normal, but not frank DM (“prediabetics,” ~40% U.S. population)

HbA1c 5.7–6.4%, impaired fasting glc (IFG) 100–125 mg/dL, or 2 h prandial glc 140–199

Preventing progression to DM: diet & exercise (58% ↓), metformin (31% ↓; _NEJM_ 2002;346:393), TZD (60% ↓; _Lancet_ 2006;368:1096)

Categories

• **Type 1** (_Lancet_ 2018;391:2449): islet cell destruction; absolute insulin deficiency; ketosis in absence of insulin; prevalence 0.4%; usual onset in childhood but can occur throughout adulthood; ↑ risk if ⊕ FHx; HLA associations; anti-GAD, anti-islet cell & anti-insulin autoAb

• **Type 2** (_Lancet_ 2017;389:2239): insulin resistance + relative insulin ↓; prevalence 6%; onset generally later in life; no HLA assoc.; risk factors: age, ⊕ FHx, obesity, sedentary lifestyle

• **Type 2 DM p**/**w DKA** (“ketosis-prone type 2 diabetes” or “Flatbush diabetes”): most often seen in nonwhite, ± anti-GAD Ab, eventually may not require insulin (_Endo Rev_ 2008;29:292)

• **M**ature-**O**nset **D**iabetes of the **Y**oung (**MODY**): autosomal dom. forms of DM due to defects in insulin secretion genes; genetically and clinically heterogeneous (_NEJM_ 2001;345:971)

• **Secondary causes of diabetes:** exogenous glucocorticoids, glucagonoma (3 Ds = DM, DVT, diarrhea), pancreatic (pancreatitis, hemochromatosis, CF, resection), endocrinopathies (Cushing’s disease, acromegaly), gestational, drugs (protease inhibitors, atypical antipsychotics)

臨床表現

• Polyuria, polydipsia, polyphagia with unexplained weight loss; can also be asymptomatic

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Diabetes 治療 Options</b></p></td></tr><tr><td><p><b>Medication</b> (↓ Hb<sub>A</sub><sub>1</sub><sub>C</sub>)</p></td><td><p><b>Comments</b></p></td></tr><tr><td><p><b>Metformin</b> (~1–1.5%)</p></td><td><p>↓ hepatic gluconeogenesis. Mild wt ↓. <i>1<sup>st</sup> line for T2D.</i> Rare lactic acidosis. Caution if GFR 30–45; contra. if &lt;30. Poss CV benefit.</p></td></tr><tr><td><p><b>DPP-4 inhibitors</b></p><p>(~0.5–1%)</p></td><td><p>Block degrad. GLP-1 &amp; GIP → ↑ insulin.</p><p>↑ risk of HF with saxagliptin <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>3;369:</span><span>1</span><span>3</span><span>1</span><span>7)</span>, not with others.</p></td></tr><tr><td><p><b>GLP-1 receptor agonists</b> (~1–1.5%)</p></td><td><p>↑ glc-depend insulin secretion. Wt ↓, N/V.</p><p>↓ CVD/MI/stroke, espec. if ASCVD. ↓ prog of albuminuria.</p></td></tr><tr><td><p><b>SGLT-2 inhibitors</b></p><p>(~0.5–1%)</p></td><td><p>↑ glucosuria. Wt ↓. Genital infxn. ↓ CVD/HHF. ↓ CVD &amp; MI if ASCVD. ↓ prog. of renal disease.</p></td></tr><tr><td><p><b>Sulfonylureas (SU)</b> (~1.5%)</p></td><td><p>↑ insulin secretion. Hypoglycemia; wt gain.</p></td></tr><tr><td><p><b>Thiazolidinediones (TZD)</b> (~1%)</p></td><td><p>↑ insulin sens. in adipose &amp; muscle. Wt ↑, fluid retention &amp; CHF. Hepatox. ↑ MI with rosiglitazone? Contraindic. in HF &amp; liver dysfxn.</p></td></tr><tr><td><p><b>Glinides</b> (~1%)</p></td><td><p>↑ insulin secretion; hypoglycemia; wt gain</p></td></tr><tr><td><p>α<b>-glucosidase inhib.</b> (0.5–1%)</p></td><td><p>↓ intestinal CHO absorption. Abd pain, flatulence.</p></td></tr><tr><td><p><b>Pramlintide</b> (~0.5%)</p></td><td><p>Delays gastric emptying &amp; ↓ glucagon. N/V</p></td></tr><tr><td><p><b>Insulin</b></p><p>(variable)</p></td><td><p>Hypoglycemia; wt gain. Mandatory in T1D; consider in T2D if oral Rx inadequate.</p></td></tr><tr><td><p>Gastric bypass</p></td><td><p>Wt ↓↓↓; can cause remission DM <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>4;370:2002)</span></p></td></tr></tbody></table>

(_Diabetes Care_ 2019;42:S90; _Lancet_ 2019;393:31; _Circ_ 2019;139:2022; _NEJM_ 2019;380:2295)

![](https://i.imgur.com/GySgk21.jpg)

Complications (_NEJM_ 2004;350:48; 2016;374:1455; _CJASN_ 2017;12:1366)

• **Retinopathy**

_nonproliferative:_ “dot & blot” and retinal hemorrhages, cotton-wool/protein exudates

_proliferative:_ neovascularization, vitreous hemorrhage, retinal detachment, blindness

治療: photocoagulation, surgery, intravitreal bevacizumab injections

• **Nephropathy:** microalbuminuria → proteinuria ± nephrotic syndrome → renal failure

diffuse glomerular basement membrane thickening/nodular pattern (Kimmelstiel-Wilson)

usually accompanied by retinopathy; lack of retinopathy suggests another cause

治療: strict BP control using ACE inhibitors or ARBs (_Mayo Clin Proc_ 2011;86:444), SGLT-2 inhib (_NEJM_ 2016;375:323 & 2019;380:2295), low-protein diet, dialysis or transplant

• **Neuropathy:** _peripheral:_ symmetric distal sensory loss, paresthesias, ± motor loss

_autonomic:_ gastroparesis, constipation, neurogenic bladder, erectile dysfxn, orthostasis

_mononeuropathy:_ sudden-onset peripheral or CN deficit (footdrop, CN III > VI > IV)

• **Accelerated atherosclerosis:** coronary, cerebral and peripheral arterial beds

• **Infections:** UTI, osteomyelitis of foot, candidiasis, mucormycosis, necrotizing external otitis

• **Dermatologic:** necrobiosis lipoidica diabeticorum, lipodystrophy, acanthosis nigricans

Outpatient screening and 治療 goals (_Diabetes Care_ 2019;42:S61, S81, S103)

• ✔ HbA1C q3–6mo, goal <7% for most 病人. Goal <6.5% if low-risk hypoglycemia; ≤8% if h/o severe hypoglycemia, elderly or other comorbid. Microvascular & macrovascular complic. ↓ by strict glycemic control in T1D (_NEJM_ 2005;353:2643) & T2D (_NEJM_ 2015;372:2197).

• Microalbuminuria screening yearly with spot microalbumin/Cr ratio, goal <30 mg/g

• Wt loss (dietary/drugs) can regress or resolve DM (_Endo Rev_ 2018;39:79; _NEJM_ 2018;379:1107)

• **BP** ≤130/80 if high CV risk, ≤140/90 if lower risk; benefit of ACEI/ARB

• **Lipids:** statin initiation in all diabetics age 40–75 if LDL-C >70 (see “Lipids”)

• ASA in 2° prevention; ? role in 1°, balancing ↓ MACE & ↑ bleeding (_NEJM_ 2018;379:1529)

• Dilated retinal exam and comprehensive foot exam yearly

Management of hyperglycemia in inPts (for ICU: see “Sepsis”) (_ClinTher_ 2013;35:724)

• Identify reversible causes/precipitants (dextrose IVF, glucocorticoids, postop, ↑ carb diet)

• Dx studies: BG fingersticks (fasting, qAC, qHS; or q6h if NPO), HbA1C

• 治療 goals: avoid hypoglycemia, extreme hyperglycemia (>180 mg/dL)

• Transition to inPt

T1D: do not stop basal insulin (can → DKA)

T2D: stopping oral DM meds generally preferred to avoid hypoglycemia or med interaction (except if short stay, excellent outPt cntl, no plan for IV contrast, 正常 diet). _If Pt with known insulin needs do not rely on sliding scale alone_ (_Diabetes Care_ 2018;41:S144).

• Starting new insulin regimen

Basal = 0.2–0.4 u/kg/d NPH Q12h or detemir or glargine

\+ correction insulin for BG >150 mg/dl

\+ prandial insulin if eating**:** 0.05–0.1 μ/kg/meal lispro, aspart, or regular

• _When NPO_

T1D: continue basal insulin at current dose or 75% depending on BG control

T2D: continue basal insulin at 25–75% depending on BG control and level of insulin resistance. Hold all prandial insulin.

• Discharge regimen: similar to admission regimen unless poor outPt cntl or strong reason for Δ. Arrange early insulin and glucometer teaching, prompt outPt follow-up.

DIABETIC KETOACIDOSIS (DKA)

Precipitants (the I’s)

• **Insulin defic.** (ie, failure to take enough insulin); **Iatrogenesis** (glucocorticoids; SGLT2 inhibitors—can be without marked hyperglycemia; _Diabetes Care_ 2016;39:532)

• **Infection** (pneumonia, UTI) or **Inflammation** (pancreatitis, cholecystitis)

• **Ischemia** or **Infarction** (myocardial, cerebral, gut); **Intoxication** (alcohol, drugs)

病生理 (_NEJM_ 2015;372:546)

• Occurs in **T1D** (and in ketosis-prone T2D); ↑ glucagon and ↓ insulin

• Hyperglycemia due to: ↑ gluconeogenesis, ↑ glycogenolysis, ↓ glucose uptake into cells

• Ketosis due to: insulin deficiency → mobilization and oxidation of fatty acids,

↑ substrate for ketogenesis, ↑ ketogenic state of the liver, ↓ ketone clearance

臨床表現 (_Diabetes Care_ 2009;32:1335 & 2016;39:S99)

• Polyuria, polydipsia, & dehydration → ↑ HR, HoTN, dry mucous membranes, ↓ skin turgor

• N/V, abdominal pain (either due to intra-abdominal process or DKA), ileus

• Kussmaul’s respirations (deep) to compensate for metabolic acidosis with odor of acetone

• Δ MS → somnolence, stupor, coma; mortality ~1% even at tertiary care centers

Diagnostic studies

• ↑ **Anion gap metabolic acidosis:** can later develop nonanion gap acidosis due to urinary loss of ketones (HCO3 equivalents) and fluid resuscitation with chloride

• **Ketosis:** ⊕ **urine and serum ketones** (predominant ketone is β-OH-butyrate, but acetoacetate measured by assay; urine ketones may be ⊕ in fasting normal 病人)

• ↑ Serum glc; ↑ BUN & Cr (dehydration ± artifact due to ketones interfering with some assays)

• Hyponatremia: corrected Na = measured Na + \[2.4 × (measured glc – 100)/100\]

• ↓ or ↑ K (but even if serum K is elevated, usually _total body K depleted_); ↓ total body phos

• Leukocytosis, ↑ amylase (even if no pancreatitis)

![](https://i.imgur.com/6jdWSMG.jpg)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>治療 of DKA</b> <span>(<i>BMJ</i> 2015;28:351)</span></p></td></tr><tr><td><p><b>排除 possible precipitants</b></p></td><td><p>Infection, intra-abdominal process, MI, etc. (see above)</p></td></tr><tr><td><p><b>Aggressive hydration</b></p></td><td><p>NS 10–14 mL/kg/h, tailor to dehydration &amp; CV status</p></td></tr><tr><td><p><b>Insulin</b></p></td><td><p>10 U IV push followed by 0.1 U/kg/h</p><p>Continue insulin drip until AG normal</p><p>If glc &lt;250 and AG still high → add dextrose to IVF and continue insulin to metabolize ketones</p><p>AG normal → SC insulin (overlap IV &amp; SC 2–3 h)</p></td></tr><tr><td><p><b>Electrolyte repletion</b></p></td><td><p>K: add 20–40 mEq/L IVF if serum K &lt;4.5 insulin promotes K entry into cells → ↓ serum K careful K repletion in 病人 with renal failure</p><p>HCO<sub>3</sub>: ? replete if pH &lt;7 or if cardiac instability</p><p>PO<sub>4</sub>: replete if &lt;1</p></td></tr></tbody></table>

HYPEROSMOLAR HYPERGLYCEMIC STATE

定義, precipitants, 病生理 (_Med Clin North Am_ 2017;101:587)

• Extreme hyperglycemia (w/o ketoacidosis) + hyperosm. + Δ MS in T2D (typically elderly)

• Precip same as for DKA, but also include dehydration and renal failure

• Hyperglycemia → osmotic diuresis → vol depletion → prerenal azotemia → ↑ glc, etc.

臨床表現 & dx studies (_Diabetes Care_ 2014;37:3214)

• Volume depletion and Δ MS

• ↑ **serum glc** (usually >600 mg/dL) and ↑ **meas. serum osmolality** (>320 mOsm/L) effective Osm = 2 × Na (mEq/L) + glc (mg/dL)/18

• No ketoacidosis; usually ↑ BUN & Cr; \[Na\] depends on hyperglycemia & dehydration

治療

• Rule-out possible precipitants; ~15% mortality due to precipitating factors

• **Aggressive hydration:** initially NS, then 1/2 NS, average fluid loss up to 8–10 L

• **Insulin** (eg, 10 U IV followed by 0.05–0.1 U/kg/h)

HYPOGLYCEMIA

臨床表現 (glucose <~55 mg/dL)

• **CNS:** headache, visual Δs, Δ MS, weakness, seizure, LOC (neuroglycopenic sx)

• **Autonomic:** diaphoresis, palpitations, tremor (adrenergic sx)

原因 in diabetics

• Excess insulin, oral hypoglycemics, missed meals, renal failure (↓ insulin & SU clearance)

• β-blockers can mask adrenergic symptoms of hypoglycemia

原因 in nondiabetics

• ↑ **insulin:** exogenous insulin, sulfonylureas, insulinoma, anti-insulin antibodies

• ↓ **glucose production:** hypopituitarism, adrenal insufficiency, glucagon deficiency, hepatic failure, renal failure, CHF, alcoholism, sepsis, severe malnutrition

• ↑ **IGF-II:** non-islet tumor

• Postprandial, esp. postgastrectomy or gastric bypass: excessive response to glc load

• Low glc without sx can be normal

Evaluation in nondiabetics (_JCEM_ 2009;94:709)

• If clinically ill: take measures to avoid recurrent hypoglycemia; ✔ BUN, Cr, LFTs, TFTs, prealbumin; IGF-I/IGF-II ratio when appropriate

• If otherwise healthy: 72-h fast with monitored blood glc; stop for neuroglycopenic sx

• _At time of hypoglycemia:_ insulin, C peptide (↑ with insulinoma and sulfonylureas, ↓ with exogenous insulin), β-OH-butyrate, sulfonylurea levels

• At end of fast, give 1 mg glucagon IV and measure response of plasma glc before feeding

治療

• Glucose tablets, paste, fruit juice are first-line Rx for 病人 who can take POs

• 25–50 g of D50 IV; if no access, glucagon 0.5–1 mg IM or SC (side effect: N/V)
